^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)

    i
    Other names: UGT1A10, UDP Glucuronosyltransferase Family 1 Member A10, UGT1J, UDP Glycosyltransferase 1 Family, Polypeptide A10, UDP-Glucuronosyltransferase 1A10, UDP-Glucuronosyltransferase 1-10, UDP-Glucuronosyltransferase 1-J, UGT1-10, UGT1.10, UGT-1J, GNT1, UGT1, UDP Glucuronosyltransferase 1 Family, Polypeptide A10, Bilirubin-Specific UDPGT Isozyme 1, UDP-Glucuronosyltransferase 1-1, UDP-Glucuronosyltransferase 1-A, UDP-Glucuronosyltransferase 1A1, UDPGT 1-10, UGT1-01, HUG-BR1, UGT1*10, UGT-1A, UGT1.1, UGT1A1, UDPGT, UGT1A
    Associations

    News

    Trials
    3ms
    Polystyrene nanoparticles promote endometrial cancer progression via downregulation of UGT1A genes. (PubMed, Chem Biol Interact)
    Collectively, our findings show that PS-NPs promote EC progression by downregulating UGT1A genes (especially UGT1A1 and UGT1A10) and disrupting the homeostasis of the steroid hormone pathway. This research not only introduces a novel perspective for interdisciplinary studies bridging environmental toxicology and gynecological oncology but also provides critical scientific insights into understanding the pathogenesis of EC, developing prevention and treatment strategies, and assessing the safety of NPs.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    8ms
    The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma. (PubMed, J Transl Med)
    This study provided a novel prognostic model for HCC, incorporating 6 representative DNLs. The model demonstrated the potential for predicting HCC prognosis and highlighted the involvement of immune cell infiltration and the association between risk scores and clinical therapy. Validation of model genes further supported the association between de novo lipogenesis and HCC development.
    Journal • IO biomarker
    |
    SERPINE1 (Serpin Family E Member 1) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • G6PD (Glucose-6-Phosphate Dehydrogenase) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    12ms
    Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment. (PubMed, J Exp Clin Cancer Res)
    Our results highlight the necessity for personalized treatment strategies that consider genomic diversity beyond tumor markers, thus validating the utility of PDOs and PDOX models in advancing PDAC research and personalized medicine.
    Journal • IO biomarker
    |
    UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    1year
    Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels (PubMed, Yakugaku Zasshi)
    Additionally, CYP and UGT expression levels may possibly affect cancer prognosis by metabolizing endogenous substrates, regardless of their role in anti-cancer drug metabolism. In this review, I discuss CYP and UGT expression level profiles in RCC based on previously published papers, including ours, and examine possible relationships between these enzyme expression profiles and treatment outcomes for patients with RCC.
    Review • Journal • IO biomarker
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    |
    UGT1A1*1*1
    over2years
    A Targetable Pathway to Eliminate TRA-1-60+/TRA-1-81+ Chemoresistant Cancer Cells. (PubMed, J Mol Cell Biol)
    Finally, TRA-1-60/TRA-1-81 expression is highly specific in primary cancer tissue and positively correlated with chemoresistance and short survival, which highlights their potentiality for targeted therapy. Therefore, we discovered a novel CCC surface marker regulated by a pathway that promotes chemoresistance, as well as a leading drug candidate to target this pathway.
    Journal
    |
    TRA (T Cell Receptor Alpha Locus) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10)
    |
    UGT1A1*1*1
    over2years
    Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. (PubMed, Chem Biol Interact)
    The quantitative prediction of DDIs risk indicated that the co-administration of tucatinib with drugs mainly metabolized by hepatic or intestinal UGTs (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B15 and UGT2B17) might result in potential DDIs risk through inhibition of glucuronidation. More attention should be paid to the influence of tucatinib on UGTs in liver and intestine to avoid unnecessary clinical DDIs risk.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)
    |
    HER-2 positive • UGT1A1*1*1
    |
    Tukysa (tucatinib)